<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603783</url>
  </required_header>
  <id_info>
    <org_study_id>METC 152005</org_study_id>
    <nct_id>NCT02603783</nct_id>
  </id_info>
  <brief_title>Esophageal capsaïcin Infusion and Mucosal Integrity</brief_title>
  <official_title>&quot;Effect of capsaïcin Infusion on Esophageal Mucosal Integrity - a Role for TRPV1-mediated Neuropeptides?&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reflux is common, especially after large meals. In general, this can do no harm. However, if&#xD;
      reflux occurs often and causes troublesome symptoms and or complications, it is called&#xD;
      gastroesophageal reflux disease (GERD). Long exposure to gastric acid causes the mucosa of&#xD;
      the esophagus to loose its integrity, which is thought to lead to the symptom of heartburn.&#xD;
      Several food products can also impair the esophageal mucosa integrity and thereby influence&#xD;
      reflux symptoms. One of these products is capsaicin, the pungent ingredient of red peppers.&#xD;
      Use of capsaicin often leads to worsening of complaints in patients with GERD and can cause&#xD;
      symptoms in healthy volunteers, possibly due to its effect on the mucosal integrity.&#xD;
&#xD;
      In this study the investigators want to investigate the effect of capsaicin infusion on&#xD;
      mucosal integrity. The investigators will evaluate mucosal impedance and the histology of the&#xD;
      esophageal mucosa. In addition, the investigators also aim to assess the involvement of the&#xD;
      TRPV1 receptor by evaluating the possible release of neuropeptides in the esophageal mucosa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in mucosal integrity in the distal exposed esophagus during capsaicin infusion compared to control solution.</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The primary outcome measure is the effect of capsaïcin infusion on mucosal integrity as reflected by baseline impedance in the distal exposed esophagus compared to control infusion.&#xD;
We hypothesize that capsaïcin infusion induces changes to the mucosa as reflected by a decrease in baseline impedance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucosal integrity in the proximal non-exposed esophagus.</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The effect of esophageal capsaïcin infusion on mucosal integrity as reflected by baseline impedance in the proximal non-exposed esophagus compared to control solution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of dilated intercellular spaces (DIS)</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The effect of esophageal capsaïcin infusion on the induction of dilated intercellular spaces (DIS) in the distal exposed and proximal non-exposed esophagus as measured with transmission electron microscopy (TEM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPV1 neuropeptide pathway</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The differences in the TRPV1 neuropeptide pathway (substance P) by radioimmunoassay (RIA) during capsaïcin infusion or control solution in both the distal exposed and proximal non-exposed esophagus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical expression of TRPV1</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The differences in immunohistochemical expression of TRPV1 during capsaïcin infusion or control solution in both the distal exposed and proximal non-exposed esophagus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>Testday 1 and 2: during capsaicin and placebo infusion.</time_frame>
    <description>The effect of capsaïcin infusion on symptoms in healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRPV1 neuropeptide pathway</measure>
    <time_frame>Testday 1 and 2: mucosal biopsies are taken during upper gastrointestinal endoscopy</time_frame>
    <description>The differences in the TRPV1 neuropeptide pathway (CGRP) by radioimmunoassay (RIA) during capsaïcin infusion or control solution in both the distal exposed and proximal non-exposed esophagus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>TRPV1 Protein, Human</condition>
  <condition>Capsaicin</condition>
  <condition>Electric Impedance</condition>
  <condition>Esophagus</condition>
  <condition>Intracellular Space</condition>
  <condition>Pain Measurement</condition>
  <condition>Microscopy, Electron</condition>
  <arm_group>
    <arm_group_label>Capsaicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,5 mg capsaicin in 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75 ml placebo (0,9 % saline) in 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>capsaicin 1,5 mg</description>
    <arm_group_label>Capsaicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0,9% saline 75 ml</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No history of gastrointestinal disease, especially gastro-esophageal reflux disease.&#xD;
&#xD;
          -  BMI = 18-25 kg/m²&#xD;
&#xD;
          -  Caucasian race&#xD;
&#xD;
          -  Subject signed the informed consent form and is able to adhere to study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Erosive esophagitis or gastric ulceration during endoscopy on PPI in the past or&#xD;
             during the experiment&#xD;
&#xD;
          -  Use of regular (&gt; 1 x per week) dietary capsaïcin (in additives as&#xD;
             Tabasco/sambal/chili sauce or Indian, Mexican or Thai food dishes)&#xD;
&#xD;
          -  Allergy to capsaïcin&#xD;
&#xD;
          -  Use of medication affecting GI function (prokinetics) or antisecretory medication&#xD;
             (PPI) within 3 days prior to endoscopy.&#xD;
&#xD;
          -  Multisystem diseases (including severe cardiopulmonary disease, collagen diseases,&#xD;
             coagulation disorders)&#xD;
&#xD;
          -  Esophageal motility disorders&#xD;
&#xD;
          -  Previous esophageal or gastric surgery&#xD;
&#xD;
          -  Use of anticoagulants or a history of coagulopathy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of alcohol abuse or current excessive alcohol consumption (&gt; 2 alcoholic&#xD;
             beverages per day or &gt; 14 alcoholic beverages per week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Conchillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center (MUMC+)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

